Skip to main content
. 2021 Jun 4;11:689587. doi: 10.3389/fonc.2021.689587

Figure 2.

Figure 2

Percentage of patients with HER2-positive early-stage breast cancer who achieved a pCR following CT-P6 or RTZ treatment, stratified by HR status for (A) all patients and (B) propensity score matching cohort. HER2, human epidermal growth factor receptor 2; HR, hormone receptor; pCR, pathologic complete response; RTZ, reference trastuzumab.